Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable
Executive Summary
FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act
You may also be interested in...
Drug Proprietary Name Selection: Draft Guidance Calls For Simulation Studies
FDA draft guidance on developing proprietary drug names recommends series of steps for sponsors to evaluate a proposed name; safety review includes testing name with healthcare professionals.
PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown
The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.
PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown
The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.